Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Equity Ratio (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Equity Ratio for 6 consecutive years, with 0.92 as the latest value for Q3 2025.

  • Quarterly Equity Ratio rose 855.51% to 0.92 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 0.92 through Sep 2025, up 855.51% year-over-year, with the annual reading at 0.96 for FY2024, 27.14% up from the prior year.
  • Equity Ratio for Q3 2025 was 0.92 at Inhibikase Therapeutics, up from 0.9 in the prior quarter.
  • The five-year high for Equity Ratio was 0.96 in Q4 2024, with the low at 0.12 in Q3 2024.
  • Average Equity Ratio over 5 years is 0.79, with a median of 0.88 recorded in 2022.
  • The sharpest move saw Equity Ratio tumbled 114.43% in 2024, then surged 855.51% in 2025.
  • Over 5 years, Equity Ratio stood at 0.9 in 2021, then fell by 6.74% to 0.84 in 2022, then fell by 10.29% to 0.76 in 2023, then increased by 27.14% to 0.96 in 2024, then fell by 4.81% to 0.92 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.92, 0.9, and 0.91 for Q3 2025, Q2 2025, and Q1 2025 respectively.